Wet Granulation Endpoint Control for Mupirocin Tablet Blends

Granulation of mupirocin free acid in a high-shear mixer fitted with a jacketed vessel is performed with a 2-propanol aqueous granulating fluid containing povidone K30 at 2.0–3.5 wt% of the dry granulate mass. The free acid has low aqueous solubility at pH below 5.0, so a soluble sodium citrate buffer component at 10–15 wt% is dry-blended into the formulation to raise the microenvironmental pH of the granule to 5.5–6.0 during dissolution testing; this adjustment reduces acid-catalysed ester cleavage without exceeding the pH range accepted by the film-coating polymer. Endpoint is not determined by fixed massing time but by the power draw differential on the main impeller: a torque rise of 2–3 N·m above the dry-mix baseline corresponds to granule densification and liquid saturation within 80%–90% of the mass, after which additional fluid produces overwetting and sieve-blocking agglomerates larger than 1.0 mm. The wet mass is discharged and dried in a fluid-bed dryer with inlet air at 40–45 °C and product temperature held at 30–35 °C to avoid thermolabile degradation of the ester and epoxide functionalities; drying is terminated at loss on drying 1.5%–2.5% w/w per USP <731>. Compression on a rotary tablet press at 60–80 N hardness for a 10 mm round convex tooling produces tablets with disintegration time below 15 min per USP <701> and friability below 0.8% per USP <1216>.

For content uniformity, the milled granulate is required to have d10 > 75 µm, d50 150–250 µm, and d90 < 500 µm before lubricant addition; magnesium stearate is added at 0.75 wt% and blended for 5 min at 15 rpm in a diffusion mixer. Tablets are film-coated with a polyvinyl alcohol-based aqueous dispersion to 3.0% w/w weight gain, with bed temperature 42–46 °C and atomization pressure 1.0–1.5 bar. Release testing in 900 mL of pH 6.8 phosphate buffer at 50 rpm paddle speed per USP <711> typically shows not less than 80% mupirocin released at 45 min for immediate-release tablets. Batch records require in-process granule moisture, particle-size distribution, and compression force as critical process parameters because mupirocin tablet robustness is sensitive to overgranulation and residual moisture; both conditions alter tablet hardness, disintegration time, and assay variability across tray positions in long-duration compression runs.

Direct encapsulation of mupirocin calcium into hard gelatin capsules is performed only after the API is passed through a 0.5 mm screen and blended with pre-dried excipients in a temperature-controlled suite at 25–30 °C and 35%–45% relative humidity. The dihydrate calcium salt is hygroscopic and can transfer moisture to the gelatin shell, causing shell deformation and delayed dissolution if the fill mass water activity exceeds 0.4; lactose monohydrate is therefore pre-dried at 45 °C for 4 h and microcrystalline cellulose is equilibrated to 3%–5% w/w moisture before use. A representative fill formula for a 250 mg capsule contains mupirocin calcium equivalent to 20 mg free acid, lactose monohydrate 60.0 wt%, microcrystalline cellulose 25.0 wt%, croscarmellose sodium 4.0 wt%, talc 1.0 wt%, and magnesium stearate 0.5 wt%. The blend is filled on a dosator-type capsule machine with pin setting 18–20 mm and compression station set to produce a plug density of 0.65–0.75 g/cm³; fill weight rejection limits are ±3% of target. Content uniformity acceptance value AV ≤ 15 per USP <905> is applied because the low dose and poor flow of the bulk API can cause segregation when secondary blending time is extended beyond 10 min. Gelatin shell moisture content is maintained at 13%–15% w/w, and the finished capsule is packaged in aluminium/aluminium blisters with desiccant if the climatic zone exceeds 30 °C / 65% RH. Dissolution of the capsule in 900 mL of pH 6.8 phosphate buffer at 50 rpm apparatus 2 per USP <711> is used instead of simulated gastric fluid because of the acid sensitivity of the free acid; the acceptance criterion is not less than 75% released at 30 min for the immediate-release capsule. Gelatin cross-linking caused by trace aldehyde impurities is not a primary release-failure mechanism for mupirocin, but formaldehydic shell-linking can still occur after accelerated storage in oxygen-permeable packaging; dissolution testing with pepsin in the medium may be required if the capsule shell pellicle does not rupture within 15 min.

Why Does Gastric Acid Hydrolysis Constrain Oral Mupirocin Capsule Design?

Because mupirocin free acid contains an ester linkage between monic acid and 9-hydroxynonanoic acid, exposure to 0.1 M hydrochloric acid at 37 °C accelerates ester bond cleavage; the degradation products do not retain clinically relevant inhibition of bacterial isoleucyl-tRNA synthetase. An immediate-release oral capsule containing unprotected mupirocin free acid therefore shows reduced assay and antimicrobial activity after the acid stage of dissolution testing, which is why a pH-modifying formulation or enteric coating is selected when a capsule must pass through the stomach intact. The most common design response is to apply a methacrylic acid-ethyl acrylate copolymer (1:1) dispersion to a weight gain of 8%–12% w/w; the coating dispersion contains triethyl citrate at 20 wt% of polymer solids and glyceryl monostearate at 5 wt% to prevent sticking during the coating process. Coating is performed in a perforated pan with inlet air temperature 30–35 °C, product temperature 26–30 °C, and curing at 30 °C for 2 h to complete film coalescence.

Dissolution testing of the enteric capsule is run in two stages: acid stage in 750 mL of 0.1 N HCl for 2 h, followed by buffer stage after adding 250 mL of 0.2 M tribasic sodium phosphate to achieve pH 6.8, with paddle speed 50 rpm and temperature 37 °C per USP <711>. The acid stage acceptance criterion is no more than 10% mupirocin released after 2 h, and the buffer stage criterion is not less than 80% released at 45 min. If the capsule is instead formulated as a lipid-based liquid fill, the fill mass may contain medium-chain triglycerides and glyceryl monolinoleate with a hydrophilic surfactant such as polysorbate 20 at 5%–10% w/w; the liquid-filled hard capsule is assessed for phase separation after 3 freeze-thaw cycles between −20 °C and 25 °C. Published data for mupirocin lipid-based oral dosage forms is limited; therefore, formulation work requires forced degradation bracketing under acidic and oxidative stress conditions before committing to a fill formulation.

Granule sachet formulations for oral suspension are manufactured by extrusion-spheronization or by fluid-bed layering onto inert sugar spheres; the selection depends on the dose-to-fill ratio and the need to mask the bitter taste of the API. Extrusion-spheronization with microcrystalline cellulose at 35 wt%, lactose monohydrate at 45 wt%, and hypromellose 5 cP at 5 wt% as binder produces pellets of d50 0.8–1.2 mm and sphericity above 0.85; the spheronization plate speed is set at 800–1,000 rpm until the pellet surface becomes smooth, after which the product is dried at 35 °C to loss on drying below 2.0% w/w. Fluid-bed layering is preferred when a lower sphericity is acceptable and when the API is micronized to d90 ≤ 25 µm by jet milling; the binder solution of hypromellose is sprayed at 5 wt% solids with a spray rate of 8–12 g/min/kg of substrate and a product temperature of 28–32 °C. The finished granule sachet contains mupirocin calcium equivalent to 50 mg free acid per 1.0 g fill mass, with sucralose 0.2 wt%, xanthan gum 0.3 wt%, citric acid 1.0 wt%, and a flavour system below 0.5 wt%. Loss on drying is controlled at 1.5%–2.0% w/w per USP <731>, and the sachet is sealed under nitrogen to reduce oxidative degradation of the epoxide. Suspension uniformity is evaluated by dispersing one sachet in 20 mL of potable water at 25 °C, stirring for 30 s, and sampling after 5 min; the assay of the top and bottom fractions should differ by no more than 5% of label claim. The delivered dose from the sachet is tested for content uniformity AV ≤ 15 per USP <905>, and microbial limits follow USP <61> and USP <62> for non-sterile oral products.

When Terminal Sterilization of a Mupirocin Injection Is Not Feasible

Injectable dosage forms of mupirocin are constrained by the fact that the molecule is hydrolysed by serum esterases, so injectable formulations are not used for systemic therapy; they are confined to in vitro susceptibility testing panels, experimental pharmacokinetic studies in animal models, or local irrigation under a licensed indication. Terminal steam sterilization at 121 °C for 15 min is not compatible with the ester and epoxide functionalities in aqueous solution; forced degradation at 121 °C and pH 7.0 shows unacceptable loss of assay and appearance of monic acid and 9-hydroxynonanoic acid cleavage products. The sterile bulk solution is therefore processed by aseptic filtration through a 0.22 µm PVDF or PES membrane; filter integrity is tested before and after filtration by bubble point per ASTM F838-20, and the filtered solution is held at 2–8 °C for no more than 24 h before lyophilization or filling if the solution is not self-sterilized.

The fill solution contains mupirocin sodium or mupirocin free acid adjusted to pH 6.8–7.2 with 0.1 N sodium hydroxide, mannitol as an isotonic bulking agent at 50 mg/mL, and water for injection to final volume; the fill volume is 2 mL in Type I borosilicate glass vials with chlorobutyl stoppers. In-use stability after reconstitution is tested at 25 °C and 60% RH for 6 h, and the acceptance criterion is not less than 95.0% of initial assay. The table below lists the release tests applied to a mupirocin injectable solution, including bacterial endotoxins and particulate matter limits required for a terminally sterilized alternative.

Aseptic processing validation follows EU GMP Annex 1 with media fill acceptance of no more than 1 contaminated unit per 10,000 filled units, and the environmental monitoring limits for Grade A zones set at 3,520 particles/m³ for ≥0.5 µm during operation per ISO 14644-1 Class 5. Batch-to-batch variance in filter binding and solution viscosity is controlled by filtering at constant pressure ≤ 2 bar and by measuring filter integrity before discard.

A Lyophilization Cycle Is Defined by the Glass Transition Temperature of the Frozen Matrix

In a lyophilization cycle for a mupirocin sodium formulation, the freezing rate and annealing step are determined by the glass transition temperature of the maximally freeze-concentrated solution, Tg′, measured by modulated differential scanning calorimetry at -32 °C for a formulation containing mannitol 50 mg/mL and sodium citrate 5 mM. The solution is frozen to -45 °C at 0.5 °C/min, and annealing at -15 °C for 2 h is applied to promote mannitol crystallisation and reduce vial breakage caused by differential thermal expansion across the frozen cake. Primary drying is conducted with shelf temperature at -20 °C and chamber pressure at 0.20 mbar; product temperature is held below -25 °C for the entire sublimation phase, which for a 10 mL fill in a 20 mL vial requires 24–36 h at a sublimation rate of 0.05–0.10 mm/h. Secondary drying at 25 °C shelf temperature for 6 h reduces residual moisture to 1.0%–2.0% w/w by Karl Fischer titration.

Cake appearance is evaluated as a critical quality attribute: an off-white intact cake without collapse or meltback indicates that the product temperature did not exceed the collapse temperature during primary drying. Reconstitution with 10 mL water for injection should produce a clear solution within 60 s; delayed reconstitution above 120 s is a signal of overdrying or phosphate buffer crystallisation. Stopper moisture content after steam sterilization is held below 0.5% w/w to avoid water transfer into the lyophilized cake during shelf storage, and the closure system is checked for container-closure integrity by dye ingress or helium leak testing per USP <1207>. Batch release includes assay by HPLC per USP <621>, related substances, bacterial endotoxins ≤ 0.25 EU/mg, and sterility per USP <71>; the lyophilized injection is stored at 2–8 °C, and freeze-thaw cycling is not recommended because the reconstituted solution undergoes ester hydrolysis if held above 25 °C for more than 6 h.